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Background: An epidemic of human papillomavirus (HPV)-related oropharyngeal squamous cell cancer (OPSCC)
has been reported worldwide largely due to oral infection with HPV type-16, which is responsible for approximately
90% of HPV-positive cases. The purpose of this study was to determine the rate of HPV-positive oropharyngeal
cancer in Southwestern Ontario, Canada.
Methods: A retrospective search identified ninety-five patients diagnosed with OPSCC. Pre-treatment biopsy
specimens were tested for p16 expression using immunohistochemistry and for HPV-16, HPV-18 and other high-risk
subtypes, including 31,33,35,39,45,51,52,56,58,59,67,68, by real-time qPCR.
Results: Fifty-nine tumours (62%) were positive for p16 expression and fifty (53%) were positive for known high-risk
HPV types. Of the latter, 45 tumors (90%) were identified as HPV-16 positive, and five tumors (10%) were positive for
other high-risk HPV types (HPV-18 (2), HPV-67 (2), HPV-33 (1)). HPV status by qPCR and p16 expression were
extremely tightly correlated (p < 0.001, Fishers exact test). Patients with HPV-positive tumors had improved 3-year
overall (OS) and disease-free survival (DFS) compared to patients with HPV-negative tumors (90% vs 65%, p = 0.001;
and 85% vs 49%, p = 0.005; respectively). HPV-16 related OPSCC presented with cervical metastases more frequently
than other high-risk HPV types (p = 0.005) and poorer disease-free survival was observed, although this was not
statistically significant.
Conclusion: HPV-16 infection is responsible for a significant proportion of OPSCC in Southwestern Ontario. Other
high-risk subtypes are responsible for a smaller subset of OPSCC that present less frequently with cervical
metastases and may have a different prognosis.
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The incidence of head and neck squamous cell carcin-
oma is generally decreasing [1,2], likely due to declining
rates of smoking and alcohol use. An exception to this
trend has been cancers affecting the oropharynx, which
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reproduction in any medium, provided the orover the last three decades [3,4]. Infection by human
papillomavirus (HPV) has been implicated as the cause
of this dramatic rise in oropharyngeal squamous cell car-
cinomas (OPSCC), particularly those affecting the palat-
ine and lingual tonsils [3]. Importantly, numerous
studies have reported improved survival for patients with
HPV-positive tumors [3,5,6]. Of the several high-risk
strains of HPV identified, approximately 90 percent of
HPV-positive OPSCC is attributed to type 16, while
other types are rare [7].
There is a wide discrepancy in the fraction of OPSCC
that are HPV-positive world-wide, with incidence ratesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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America, most reports suggest that the incidence is ap-
proximately 60 percent [5,6]. These differences may be
attributed to geographic population-based differences, as
well as the varying sensitivity and specificity of different
detection methods for the presence of HPV. We endea-
voured to study patients from our catchment area in
Southwestern Ontario, Canada to determine the inci-
dence of HPV-related OPSCC and confirm whether
HPV status conferred a survival advantage.
Methods
Study population
Study approval was obtained from the University of
Western Ontario Research Ethics Board. A retrospective
search of the London Regional Cancer Program (LRCP)
database was performed to identify patients diagnosed
with OPSCC from 2003 to 2009. Patient eligibility
required: 1) a histologically confirmed diagnosis of squa-
mous cell carcinoma, 2) no prior history of head and
neck cancer, and 3) the availability of a pre-treatment
primary site biopsy specimen for analysis. Patient data
was extracted from a retrospective chart review, which
included age at diagnosis, use of tobacco and alcohol,
AJCC TNM stage, treatment regimen, and post-treatment
follow-up information.
After the completion of cancer therapy, patients were
followed closely at six to twelve week intervals by either
a radiation oncologist or head and neck surgeon. Treat-
ment response was evaluated by physical exam as well as
computed tomography imaging as needed. Salvage neck
dissection was undertaken within three months of the
completion of radiation treatment if evidence of re-
sidual adenopathy was present radiographically or on
physical exam. The presence of neck disease more than
three months after diagnosis was considered a regional
persistence.
Deparaffinization
The formalin fixed paraffin embedded blocks from each
patient’s primary site were sectioned (5 μm thick) and
mounted on slides. The slides were then deparaffinized
with 3 minute washes in xylene (100%) twice, followed
by a 1:1 xylene:ethanol mix, then ethanol (100%) twice,
followed by single washes in ethanol at 95%, 70% and
50%. Lastly, the slides were washed in water for 5
minutes.
p16 immunohistochemistry
Citrate buffer was applied to the deparaffinized slides for
heat induced epitope retrieval for 30 minutes, followed
by treatment with 0.1% Triton X-100 in PBS. Endogen-
ous biotin was quenched using an avidin/biotin kit (Bio-
care Medical, Concord CA,USA) and the endogenousperoxidase activity was blocked by H202 prior to primary
antibody incubation. Specimens were incubated with a
primary mouse monoclonal antibody against human p16
(MTM Laboratoris, Heidelberg, Germany) at 1:500 dilu-
tion. The Vectastain ABC kit, with a goat anti mouse
secondary antibody, was used as per the manufacturer’s
instructions. Antigen detection was done using diamino-
benzidine chromogen (Biocare Medical, Concord, CA).
Tissues were counterstained with Carazzi’s hematoxylin.
Immunohistochemistry scoring was conducted by two
head and neck pathologists (KK and BW) blinded to
HPV status and patient outcome. Scoring was as
described by Begum et al., with strong and diffuse stain-
ing (>80 percent of tumour cells) regarded as a positive
result, and negative if absent or focal [9].DNA extraction
Deparaffinized tissue was scraped into a 1.5 ml eppen-
dorf tube containing 50–100 μl (depending on the
amount of tissue) of TE and proteinase K (final concen-
tration 2 mg/ml) and incubated overnight at 65°C. Fol-
lowing proteinase K treatment, the samples were heated
at 95°C for 10 minutes and allowed to cool to room
temperature. 0.2 μl of each sample was used directly in
the qPCR reactions.High-risk HPV detection by multiplex qPCR
In an effort to screen clinical samples for the presence of
human papillomavirus (HPV), we designed a multiplex
quantitative PCR to identify those samples that were
HPV positive and to confirm the HPV type in the posi-
tive samples. We designed primer/probe sets (Table 1)
against a 115 nucleotide (nt) fragment within exon 6 of
GAPDH (internal control), a 110 nt region across E6-E7
of HPV-16, a 137 nt fragment across the HPV-18 E6-E7
region, and a 100 nt fragment across a region of E1 that
had a high degree of homology to high-risk HPV types
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. The
multiplex PCR reactions were run on a Stratagene
Mx3000P instrument using the conditions recom-
mended in the Quantitech Multiplex handbook (Qia-
gen). Twenty μl reactions were heated for 15 minutes at
95°C to activate the amplification enzyme. This was fol-
lowed by 40 cycles of 94°C for 60 seconds and 60°C for
90 seconds. Standard curves were produced from 10 fold
serial dilutions of CaSki cell genomic DNA. Caski cell
DNA was used as a positive control for HPV16 and
HeLa cell genomic DNA was used as the HPV18 con-
trol. All samples were first tested with the type 16 and
18 primer/probe sets. Samples that were negative for
types 16 and 18 were then tested with the broad-
spectrum primer/probe set to detect the presence of
other high-risk HPV types.
Table 1 PCR primers for HPV testing
Name Sequence 5′ to 3′
GAPDH Forward GCTCATTTGCAGGGGGGAGCC
GAPDH Reverse CTGATGATCTTGAGGCTGTTG
GAPDH Probe CY5-TCTGCCCCCTCTGCTGATGCCCCCATGTTCGTCATGGGA –BHQ2
HPV 16 Forward TTGCAGATCATCAAGAACACGTAGA
HPV 16 Reverse GTAGAGATCAGTTGTCTCTGGTTGC
HPV 16 Probe JOE-AATCATGCATGGAGATACACCTACATTGCATGA –BHQ1
HPV 18 Forward CAACCGAGCACGACAGGAACG
HPV 18 Reverse TAGAAGGTCAACCGGAATTTTCAT
HPV 18 Probe ROX-AATATTAAGTATGCATGGACCTAAGGCAACATTGCAA –BHQ2
HPV all Forward (E1) CCTATAGTACATTTAAAAGGTG
HPV all Reverse (E1) CNTGTCCAATGCCAGGTAGATG
HPV all Probe (E1) FAM-AATAGTTTAAAATGTTTAAGATATAG-BHQ1
HPV other Forward (E2) GCATTATATTGGTATAGAACAGG
HPV other Reverse (E2) TCATTRTCASATGCCCATTGYACC
HPV human papillomavirus; R puRine (A or T); S Strong (C or G); Y pYrimidine (C or T).
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Tumors that tested positive for HPV infection by qPCR
with the broad spectrum primer/probe set designed
against the E2 region of HPV were tested with a second
broad spectrum set of primers against the E1 region of
HPV by conventional PCR (Table 1). PCR reactions (20
μl) were prepared using 0.2 μl of patient template DNA
and amplified with Phusion DNA polymerase (Fisher
Scientific, Toronto, Canada) following a hotstart (98°C
for 30 sec followed by 37 cycles of 98°C for 10 sec, 55°C
for 10 sec, 72°C for 30 sec). Amplified products were
resolved on 1% agarose gels. Bands of interest were
extracted from agarose gel slices, purified on columns
(Bio Basic, Markham, Canada) and sequenced with the
appropriate primer. Results were used to query the Gen-
bank Database to identify the corresponding HPV type.
Statistical analysis
Statistical analysis was performed using SPSS with the
exact tests package (IBM, Armonk, NY). For all analyses,
a p value of 0.05 or less was considered statistically sig-
nificant. Patient variables were compared using the
Fisher exact test. Disease-free survival (DFS) was defined
as the time of completion of treatment to local, regional,
or distant recurrence. Survival curves were created using
the method of Kaplan and Meier. The Cox proportional
hazard model was used to estimate the relative hazard of
mortality or recurrence over the follow-up period and
to perform univariate and multivariate analysis. Multi-
variate analysis began with a fit to all patient variables,
followed by backward stepwise regression using the
Akaike information criterion (stepAIC function) and
retention of variables in the final model having p values
of 0.05 or less.Results
HPV-16 presents more frequently with neck metastases
than other high-risk HPV types
A total of 95 patients with OPSCC were identified. The
majority of patients were treated with organ preservation
strategies (86/95, 90.5%) as opposed to primary surgery
(9/95, 9.5%) (Table 2). Patients only underwent primary
surgery if they refused primary radiation (2), had gross
bony involvement on imaging (5) or had medical contra-
indications to radiation (2, severe scleroderma). Fifty-
nine patients had tumour biopsy specimens that were
p16 positive. Real-time qPCR for high-risk HPV types
clearly separated HPV-positive tumors (all had a cycle
threshold CT < 30) and negative tumors (CT > 35). Over-
all, fifty tumors were positive for HPV, including 45
positive for HPV-16 (90%) and 2 positive for HPV-18.
The broad-spectrum primer/probe set detected three
other HPV-positive tumors, which were determined to
be type 33 (1 tumor) and type 67 (2 tumors) by sequen-
cing of PCR products. The identification of HPV-67 was
surprising because the high-risk HPV-67 sequence was
not included in our efforts to design broad-spectrum
primers. Regardless, sequencing of the 150 nt product
was highly consistent with the published HPV-67 se-
quence by BLAST analysis [10] (p < 10-39, accession
D21208). p16-positivity was tightly correlated with HPV
status (p < 0.0001, Fishers exact test), further supporting
its use as a surrogate marker of HPV infection. Analysis
of patient characteristics and HPV-positive OPSCC
revealed associations with age <60, tonsil or base of
tongue primary site, and minimal smoking history (p <
0.05, Table 2). Patients with HPV-16-positive tumors
were compared to those with tumors positive for other
high-risk HPV types. HPV-16-positive tumors were
Table 2 Correlation of HPV status with patient and tumor factors
All high-risk HPV HPV-16 only
Patient characteristic Total Negative Positive p* Negative Positive p*
Age <60 51 16 35 <0.001 18 33 <0.001
> = 60 44 29 15 32 12
Gender Male 75 32 43 0.08 37 38 0.32
Female 20 13 7 13 7
Subsite Tonsil 21 31 0.02 23 29 0.01
Base of Tongue 10 15 12 13
Other 14 4 15 3
T Classification 1 14 4 10 0.27 4 10 0.19
2 25 11 14 14 11
3 30 18 12 19 11
4 26 12 14 13 13
N Classification 0 18 13 5 0.09 16 2 0.002
1 13 7 6 8 5
2 54 21 33 22 32
3 10 4 6 4 6
Overal Stage 1 2 1 1 0.49 1 1 0.02
2 9 5 4 8 1
3 13 8 5 10 4
4 71 31 40 31 39
Smoking never smokers 20 4 16 0.006 5 1 0.001
1-9 py 6 2 4 2 4
10-19 py 6 1 5 1 5
>20 py 57 35 22 39 18
Unknown 6 3 3 3 3
Alcohol < 21 drinks 70 30 40 0.37 34 36 0.45
(drinks/wk) >21 drinks 17 10 7 11 6
Unknown 8 5 3 5 3
Treatment CRT 62 29 33 0.78 30 32 0.55
Radiation 11 5 6 8 3
Induction + CRT 13 5 8 6 7
Surgery + CRT 5 3 2 3 2
Surgery + RT 2 1 1 1 1
Surgery 2 2 0 2 0
HPV Type 16 45 0 45 0 45
18 2 0 2 2 0
33 1 0 1 1 0
67 2 0 2 2 0
p16 Negative 35 34 1 <0.001 34 1 <0.001
Positive 59 10 49 15 44
HPV human papillomavirus, py pack years, RT radiation, CRT chemoradiation.
* Fisher exact test.
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versus 2/5, p = 0.005, Table 3). One of two HPV-18-positive
patients and one of two HPV-67-positive patients had
lymph node involvement. The sole HPV-33-positive patient
was node negative.
HPV-positive patients experience improved survival
Median follow-up time for the study was 39 months
(range: 1 to 91 months). A total of 26 of 95 patients
(27%) recurred, and eleven (42%) of these patients diedTable 3 Comparison of HPV-16 and other high-risk (non-16) H
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Age <60 35
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N Classification 0 5
1-3 45









Alcohol < 21 drinks 40




Induction + CRT 8
Surgery + CRT 2




HPV human papillomavirus, py pack years, RT radiation, CRT chemoradiation.
* Fisher exact test.of disease. Five patients died of other causes. The three-
year disease-free (DFS) and overall survival (OS) for all
patients was 75 % and 85%, respectively. Univariate ana-
lysis identified age, p16 status and the presence of any
high-risk HPV type as predictors of disease-free and
overall survival (Table 4 and Figure 1A and 1B). Three
year DFS and OSP rates for patients with HPV-positive
versus HPV-negative tumors were 85% vs 49%, and 90%
vs 65%; respectively. p16 positivity was also associated
with improved DFS and OS (p < 0.05, Table 4 andPV types
HPV-Positive


































Table 4 Univariate and multivariate relations to disease free survival
DFS (Univariate analysis) DFS (Multivariate analysis)
HR (95% CI)* P** HR (95% CI)* P**
Age > = 60 vs <60 3.34 (1.44-7.71) 0.01
Sex Male vs Female 1.06 (0.40-2.81) 0.91
Site Tonsil, BOT vs Other
T stage 3,4 vs 1,2 1.00 (0.46-2.17) 0.99
N stage N + vs N0 0.51 (0.22-1.18) 0.11
Smoking >10 py vs < 10 py or unknown 1.54 (0.64-3.72) 0.34
Alcohol >21 drinks vs <21 drinks and Unknown 0.94 (0.33-2.75) 0.92
p16 Positive vs Negative 0.41 (0.19-0.90) 0.025
All High-Risk HPV Positive vs Negative 0.25 (0.11-0.58) 0.001 0.24 (0.10-0.56) 0.001
HPV 16 only Positive vs Negative 0.27 (0.11-0.65) 0.003
OS (Univariate Analysis) OS (Multivariate Analysis)
HR (95% CI)* P** HR (95% CI)* P**
Age > = 60 vs <60 3.05 (1.06-8.80) 0.04
Sex Male vs Female 0.70 (0.23-2.17) 0.53
Site Tonsil, BOT vs Other 1.38 (0.39-4.90) 0.61
T stage 3,4 vs 1,2 1.76 (0.61-5.07) 0.30
N stage N + vs N0 0.37 (0.13-1.01) 0.05
Smoking >10 py vs < 10 py or unknown 2.34 (0.67-8.25) 0.19
Alcohol >21 drinks vs <21 drinks and Unknown 1.16 (0.33-4.09) 0.81
p16 Positive vs Negative 0.24 (0.09-0.67) 0.006
All High-Risk HPV Positive vs Negative 0.20 (0.06-0.62) 0.005 0.19 (0.06-0.60) 0.004
HPV 16 only Positive vs Negative 0.17 (0.05-0.59) 0.006
DFS disease-free survival, OS overal survival, HR hazard ratio, CI confidence interval, py pack years, HPV human papillomavirus.
*CI (confidence interval) by Cox proportional hazard analysis.
**Wald test.
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risk HPV infection as the only independent predictor of
disease-free and overall survival (p = 0.001 and p = 0.004,
respectively, Table 4). As multiple treatments were used,
we repeated the survival analysis using only the data
from the sixty-two patients that received platinum-based
concurrent chemoradiation to remove this potential con-
founding factor. High-risk HPV infection once again was
the only predictor of overall and disease-free survival
(p < 0.005, data not shown).
Seven of 45 HPV-16-positive patients recurred, while
none of the five patients with tumors due to non-16 high-
risk HPV types developed a recurrence (DFS 83.3% vs
100%, p = 0.94, Figure 2A). No difference in overall survival
between the HPV-16 and the HPV-other high-risk group
was detected (Figure 2B). The only death in the patients
with non-16 HPV-positive tumors was due to a myocardial
infarction in an 87-year-old patient 13 months after diag-
nosis. Together, these data confirm the significance of HPV
as a prognostic factor in OPSCC, and suggests that stage at
presentation may differ between high-risk HPV types.Discussion
Recent studies have clearly described the current epi-
demic of HPV-positive oropharyngeal squamous cell car-
cinoma (OPSCC) in North America and beyond [3,4].
Using tumors from patients from three American popu-
lation based cancer registries in the Surveillance, Epi-
demiology and End Results (SEER) program, Chaturvedi
et al [3] conclusively demonstrated that HPV-positive
OPSCC has increased markedly (225%) over the last
three decades. Improved survival for patients with HPV-
positive OPSCC was reported and our results agree with
this finding. Patients tend to be younger, non-smokers,
and non-drinkers with low rates of comorbid illness
[3,5,6]. The observed high cure rates in this high func-
tioning cohort of younger patients has led to an
increased emphasis on post-treatment quality of life, as
treatment side effects will potentially need to be endured
for decades. Consequently, several studies have been
initiated with the goal of the long-term sequelae of ther-
apy for patients with HPV-positive OPSCC, such as the
substitution of cetuximab for cisplatin in RTOG-1016.
Figure 1 Disease-free and overall survival by HPV status (A and B) and p16 status (C and D).
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cumb to disease following conventional therapy. Ang et al
[5] demonstrated that 21.2% of patients with HPV-positive
tumors relapsed within 3 years, with 13.6% of these cases
due to locoregional recurrence, and 8.7% due to the devel-
opment of distant metastases. The biological reasons for
this difference in treatment effectiveness are poorly under-
stood. A partial explanation may be the specific HPV type
implicated. In cervical cancer, HPV types 18 and 58 are
associated with a poorer prognosis, while HPV-31 portends
improved survival compared with HPV-16 [11-13]. To date
only one study has demonstrated investigated a differential
response or clinical presentation by HPV type in head and
neck cancer. Rautava et al., retrospectively analyzed 106
patients with tumors from multiple head and neck sites in-
cluding 31 oropharyngeal patients [14]. HPV genotyping
was performed with a Luminex based MultimetrixW geno-
typing kit. In contrast with most studies, they found a veryFigure 2 Disease-free (A) and overall survival (B) for HPV-positive pathigh rate of infection in non-oropharyngeal sites including
the oral cavity (76%) and larynx (40%), as well as very high
rate of co-infection (44%) and the presence of low-risk sub-
types 6 and 11 (20%) [2,15]. HPV was not found to be pre-
dictive of survival and there was no difference in outcome
based on HPV type [14].
Although limited conclusions can be drawn given the
small numbers of HPV types other than HPV-16 in our
cohort, our data suggests that HPV-16 cancers may
present more frequently with lymph node metastases and
may have a poorer outcome compared with non-16 high-
risk HPV types. Given the low frequency of HPV-positive
OPSCC presentations that are not due to HPV-16, a very
large multi-institutional series with HPV genotyping
would need to be assembled in order to answer this ques-
tion definitively.
A tremendous step forward in the battle against the
multiple cancers caused by HPV is the implementation ofients stratified by HPV type.
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HPV vaccine is highly effective in preventing benign and
precancerous lesion lesions due to HPV types 6, 11, 16
and 18 including cervical and anal dysplasia [16,17]. Due
to the significant lag time between infection and the devel-
opment of malignancy, it will take decades to determine if
these vaccines are effective in preventing anogenital and
head and neck cancers. Indeed, most individuals develop
HPV infection in their teens and twenties [18], however
the average age of diagnosis of HPV-positive patients in
our study was 58 years (range, 43–86). Due to this signifi-
cant time gap as well as low rates of use of this vaccine in
both males and females, the burden of HPV-related can-
cers will be an important clinical problem for the foresee-
able future.
HPV-positive cancers are fundamentally distinct from
traditional tobacco and alcohol related cancers [2]. Viral
oncogenes E6 and E7 cause the degradation of wild-type
p53 and pRb, respectively, while p16 is overexpressed.
This is in contrast to frequent mutations of p53 and loss
of p16 seen in conventional head and neck cancer [2].
The differences between HPV-positive and conventional
head and neck cancers was further highlighted in two
landmark papers by Stransky and Agrawal that reported
large-scale whole exome sequencing of head and neck
cancers [19,20]. These studies revealed approximately a
two to four-fold increase in number of mutations in
HPV-negative compared with HPV-positive cancers and
confirmed the differences in p53 and p16 outlined
above. Despite these differences, there were significant
overlaps in the mutational profiles of the two cancer
types, including mutations in the NOTCH receptors
(NOTCH1-3), HRAS, and PIK3CA that were seen in both
HPV-positive and negative disease. Potentially, high-
throughput technologies including expression microar-
rays, RNA-seq, and exome sequencing of large cohorts of
HPV-positive OPSCC can identify biomarkers of local, re-
gional and distant relapse as well as biological differences
between cancers due to different HPV types. Patients at
high-risk of failure could undergo treatment intensifica-
tion with the goal of increasing survival, while low-risk
patients could have their treatment de-intensified in order
to optimize post-treatment quality of life. This would be a
significant step towards customized care for patients with
HPV-positive HNSCC.
Conclusions
HPV infection is the etiologic factor for a significant
proportion of OPSCC in Southwestern Ontario as has
been observed worldwide. The majority of cases are at-
tributable to HPV-16, while other high-risk subtypes are
responsible for the remainder. HPV-16-positive OPSCC
may present at a more advanced stage than those due to
other high-risk HPV types. Larger studies are requiredto confirm this observation and determine if different
HPV types influence prognosis.
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